Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of pediatric patients previously treated with everolimus in CRAD001M2301
2013-003795-13Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus in subependymal giant cell astrocytoma (SEGA) and tuberous sclerosis complex (TSC), sponsored by Novartis. Primary endpoint: Percentage of patients who achieved Tanner Stage V at or before age 16 for females or age 17 for males. Started Nov 2014; status: completed.
02
Drugs
everolimus
03
Conditions
subependymal giant cell astrocytoma (SEGA)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2013-003795-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003795-13.